• H foundation
• K08AR081391 NIAMS NIH HHS

• Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID)
• glioma
• mental health
• oncology
• psycho‐oncology
• structured clinical interview

• Humans
• Glioma/epidemiology
• Glioma/complications
• Glioma/pathology
• Glioma/psychology
• Male
• Female
• Middle Aged
• Mental Disorders/epidemiology
• Mental Disorders/complications
• Brain Neoplasms/epidemiology
• Brain Neoplasms/psychology
• Brain Neoplasms/complications
• Adult
• Comorbidity
• Aged
• Neoplasm Grading
• Young Adult

• 01VSF18011 Innovation Fund
• Innovation Fund

• brain tumor
• language
• memory
• quality of life
• subjective deficits

• Combination therapy
• Tumour
• oHSV

• CHI3L1
• bioinformatics
• glioma

• Chitinase-3-Like Protein 1/genetics
• Chitinase-3-Like Protein 1/metabolism
• Humans
• Glioma/genetics
• Glioma/metabolism
• Glioma/pathology
• Biomarkers, Tumor/genetics
• Biomarkers, Tumor/metabolism
• Prognosis
• Gene Expression Regulation, Neoplastic
• Brain Neoplasms/genetics
• Brain Neoplasms/metabolism
• Brain Neoplasms/pathology
• Female
• Male
• Middle Aged
• Cell Line, Tumor
• Gene Expression Profiling

• 81771316 National Natural Science Foundation of China

• Glioblastoma
• MRI
• Neuro-oncology
• Neurology
• Radiology

• Humans
• Glioblastoma/diagnostic imaging
• Glioblastoma/pathology
• Male
• Female
• Middle Aged
• Brain Neoplasms/diagnostic imaging
• Brain Neoplasms/pathology
• Aged
• Adult
• Multiparametric Magnetic Resonance Imaging
• Magnetic Resonance Imaging/methods
• Prognosis
• Retrospective Studies
• Radiomics

• Humans
• Glioma/diagnostic imaging
• Glioma/therapy
• Glioma/pathology
• Glioma/diagnosis
• Prognosis
• Brain Neoplasms/diagnostic imaging
• Brain Neoplasms/pathology
• Neural Networks, Computer
• Deep Learning
• Magnetic Resonance Imaging/methods
• Image Processing, Computer-Assisted

• Humans
• Quality of Life
• Prospective Studies
• Glioma/radiotherapy
• Brain Neoplasms/radiotherapy
• Progression-Free Survival

• brain cancer
• high-grade glioma
• screening
• supportive care
• unmet needs

• Brain cancer Rehabilitation, Assessment
• Intervention of Survivor Needs
• Medical Research Future Fund
• Brain Cancer Survivorship

• Artificial intelligence
• Bevacizumab
• Glioblastoma
• Neurocognitive
• Pseudoprogression
• Radiomics
• Response assessment
• Seizure

• Bulk RNA-seq
• Immune status
• NKT cells marker genes
• Prognostic model
• ScRNA-seq

• Humans
• Glioblastoma/genetics
• Natural Killer T-Cells
• Prognosis
• Base Sequence
• RNA-Seq
• Tumor Microenvironment/genetics

• cancer
• glioma
• quality of life
• sleep
• sleep disturbance
• tumor location

• radiotherapy
• cancer models

• Brain tumor
• Cognition
• Patient-reported outcomes
• Quality of life
• Radiation therapy

• Brain tumor
• Neuro-oncology
• Neurocognitive function
• Neuropsychology
• Quality of life

• Brain Neoplasms
• Humans
• Quality of Life

Choriocarcinoma is a subtype of gestational trophoblastic disease, gestational trophoblastic neoplasia. Patients with brain metastasis are rare and information on the optimal treatment and patient outcome is limited. In order to improve the prognosis of this disease, accurate and timely treatments are very important for the patient of brain metastasis by choriocarcinoma.

A 17-year-old unmarried girl was misdiagnosed with a cerebral hemangioma with intracranial hemorrhage in a local hospital after presentation with severe head pain. She underwent craniotomy three times for treatment. The pathological results of posterior intracranial hematoma showed choriocarcinoma, and the patient was diagnosed as choriocarcinoma (21 points in stage IV). After uterine artery embolization, etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy for 7 cycles, and whole brain radiotherapy, the patient achieved remission. She has been followed for 2 years with no signs of tumor recurrence.

For female patients of childbearing age with an intracranial hematoma, the possibility of brain metastasis by choriocarcinoma should be considered. It is necessary to obtain a detailed history, including menstruation, beginning age of first sex, contraception, etc. The level of β-human chorionic gonadotropin should be tested at the beginning, and a stratified treatment should be administered according to the International Federation of Gynecology and Obstetrics staging and World Health Organization prognostic scoring systems.

• Brain metastasis
• Choriocarcinoma
• Uterine artery embolization
• Chemotherapy
• Whole brain radiotherapy
• Craniotomy
• Case report

The KNOG-1101 study showed improved 2-year progression-free survival (PFS) with temozolomide during and after radio-therapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL).

In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B).

Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33).

The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of PFS for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.

• 1p/19q co-deletion
• Anaplastic glioma
• Chemotherapy
• Quality-of-life
• Temozolomide

• Brain tumor
• Distress
• Glioma
• Neurooncology
• Quality of life
• Screening

Two methods combining survival and health-related quality of life (HRQoL) data in glioma trials to calculate the “net clinical benefit” were evaluated: Quality-adjusted effect sizes (QASES) and joint modeling (JM).

The net clinical benefit in two trials was calculated as proof of concept for other trials. With the QASES method, effect sizes for differences in progression-free survival (PFS) or overall survival (OS) and HRQoL between the experimental arm and standard treatment arm were calculated, while the relative emphasis placed on survival/HRQoL varied. JM allows simultaneous modeling of HRQoL and OS/PFS.

In the EORTC 26951 trial, combined radiochemotherapy significantly prolonged OS (difference 11.7 months), but also resulted in more patients experiencing clinically relevant worsening (≥10 points) in appetite loss and nausea/vomiting shortly after treatment. Using QASES, the survival benefit of additional procarbazine, lomustine, and vincristine (PCV) decreased from 42.3 months to 29.5 and 28.2 months when accounting for appetite loss and nausea/vomiting, respectively. JM analyses resulted in a loss of the beneficial effect of additional PCV between 13% and 24% when adjusting for different HRQoL parameters. The EORTC 22033 trial showed no significant PFS difference between radiotherapy or temozolomide alone (46 vs 39 months), nor clinically relevant differences in HRQoL. JM analyses also showed no significant association between PFS and HRQoL scales/items, whereas QASES showed that temozolomide alone was more favorable when considering symptom burden (47–49 instead of 39 months).

Both methods resulted in different outcomes, but adjusting for the impact of treatment on HRQoL resulted in theoretically reduced survival benefits.

• glioma
• joint model
• net clinical benefit
• quality of life
• survival

• Aminolevulinic Acid/administration & dosage
• Bias
• Brain Neoplasms/diagnostic imaging
• Brain Neoplasms/surgery
• Glioma/diagnostic imaging
• Glioma/surgery
• Humans
• Intraoperative Care
• Magnetic Resonance Imaging, Interventional/statistics & numerical data
• Network Meta-Analysis
• Neuronavigation/methods
• Neuronavigation/statistics & numerical data
• Optical Imaging/methods
• Optical Imaging/statistics & numerical data
• Randomized Controlled Trials as Topic/statistics & numerical data

Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions.

HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project). Change in HRQoL scores, measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN20 questionnaires, was analyzed in 3 ways: (1) at the group level, comparing mean changes in scale/item scores between treatment arms, (2) at the patient level per scale/item, calculating the percentage of patients that deteriorated, improved, or remained stable per scale/item, and (3) at the individual patient level, combining all scales/items.

Baseline and first follow-up HRQoL data were available for 3727 patients. At the group scale/item level, only the item “hair loss” showed a significant and clinically relevant change (ie, ≥10 points) over time, whereas change scores on the other scales/items were statistically significant only (all P < .001; range in change score, 0.1-6.2). Although a large proportion of patients had stable HRQoL over time (range, 27%-84%) on the patient level per scale/item, many patients deteriorated (range, 6%-43%) or improved (range, 8%-32%) on a specific scale/item. At the individual patient level, the majority of patients (86%) showed both deterioration and improvement, whereas only 1% remained stable on all scales.

Different analytical methods of changes in HRQoL result in distinct conclusions of treatment effects, all of which may be relevant for informing clinical decision making.

• brain tumor
• patient-reported outcome
• quality of life
• questionnaire

There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network “Glioma MR Imaging 2.0” (GliMR) which we present in this article.

GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current “state-of-the-art” in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019.

GliMR’s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website.

The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.

• Advanced MRI
• COST action
• Glioma
• Multi-disciplinary
• Networking
• Translational research

• CONSORT-PRO statement
• glioblastoma
• health-related quality of life
• patient-reported outcomes
• randomized controlled trials

• Age
• Distress
• Elderly patients
• Glioblastoma
• Glioma
• High-grade glioma
• Karnofsky performance status
• Quality of life

• Age Factors
• Aged
• Aged, 80 and over
• Brain Neoplasms/pathology
• Brain Neoplasms/psychology
• Cognitive Dysfunction/pathology
• Cognitive Dysfunction/psychology
• Fatigue/pathology
• Fatigue/psychology
• Female
• Glioblastoma/pathology
• Glioblastoma/psychology
• Humans
• Male
• Neoplasm Grading
• Prospective Studies
• Quality of Life
• Surveys and Questionnaires

• Friedhelm Frees Stiftung (DE)

• Brain tumours
• Mindfulness
• Psychological well-being
• Quality of life

• IDH mutation
• astrocytoma
• glioma
• lower-grade
• oligodendroglioma

Few studies have assessed fatigue in relation to glioma surgery. The purpose of this study was to explore the prevalence of pre- and postoperative high fatigue, perioperative changes, and factors associated with pre- and postoperative high fatigue in patients undergoing primary surgery for diffuse glioma.

A total of 112 adult patients were prospectively included. Patient-reported fatigue was assessed before and one month after surgery using the cancer-specific European Organization for Research and Treatment of Cancer questionnaire fatigue subscale. The scores were dichotomized as high fatigue (≥ 39) or low fatigue (< 39). A change in score of ≥ 10 was considered as a clinically significant change. Factors associated with pre- and postoperative high fatigue were explored in multivariable regression analyses.

High fatigue was reported by 45% of the patients preoperatively and by 42% of the patients postoperatively. Female gender and low Karnofsky Performance Status (KPS) were associated with preoperative high fatigue, while postoperative complications, low KPS and low-grade histopathology were associated with postoperative high fatigue. In total 35/92 (38%) patients reported a clinically significant improvement of fatigue scores after surgery, 36/92 (39%) patients reported a clinically significant worsening of fatigue scores after surgery, and 21/92 (23%) patients reported no clinically significant change in fatigue scores after surgery. Patients with low-grade gliomas more often reported low fatigue before surgery and high fatigue after surgery, while patients with high-grade gliomas more often reported high fatigue before surgery and low fatigue after surgery.

Our findings indicate that fatigue is a common symptom in patients with diffuse glioma, both pre- and postoperatively. Perioperative changes were frequently seen. This is important knowledge when informing patients before and after surgery.

The online version of this article (10.1007/s11060-020-03403-0) contains supplementary material, which is available to authorized users.

• Brain neoplasms
• Fatigue
• Glioma
• Perioperative period
• Surgery

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Brain Neoplasms/epidemiology
• Fatigue/epidemiology
• Female
• Glioma/epidemiology
• Humans
• Karnofsky Performance Status
• Male
• Middle Aged
• Perioperative Period
• Postoperative Complications/epidemiology
• Postoperative Period
• Prospective Studies
• Surveys and Questionnaires
• Young Adult

• brain tumor
• high-grade glioma
• patient-reported outcome measures
• symptom management

• Caring dilemmas
• changed caring relationship
• ethics
• malignant brain tumour
• qualitative research
• spouses

• Brain Neoplasms
• Deep Learning
• Humans
• Image Processing, Computer-Assisted
• Neural Networks, Computer

• U54 MH091657 NIMH NIH HHS

• Brain tumour
• Glioma
• Health-related quality of life (HRQoL)
• Prognostic factor
• Survival

• depression
• glioblastoma
• health-related quality of life
• miR-34a expression
• prognosis
• survival

Background: Recent studies have shown that alterations in executive function and attention lead to balance control disturbances. One way of exploring the allocation of attention is to record eye movements. Most experimental data come from a free viewing of static scenes but additional information can be leveraged by recording eye movements during natural tasks. Here, we aimed to provide evidence of a correlation between impaired visual alteration in natural tasks and postural control in patients suffering from Radiation-Induced Leukoencephalopathy (RIL).

Methods: The study subjects were nine healthy controls and 10 patients who were diagnosed with RIL at an early stage, with isolated dysexecutive syndrome without clinically detectable gait or posture impairment. We performed a balance evaluation and eye movement recording during an ecological task (reading a recipe while cooking). We calculated a postural score and oculomotor parameters already proposed in the literature. We performed a variable selection using an out-of-bag random permutation and a random forest regression algorithm to find: (i) if visual parameters can predict postural deficit and, (ii) which are the most important of them in this prediction. Results were validated using the leave-one-out cross-validation procedure.

Results: Postural scores indeed were found significantly lower in patients with RIL than in healthy controls. Visual parameters were found able to predict the postural score of RIL patients with normalized root mean square error (RMSE) of 0.16. The present analysis showed that horizontal and vertical eye movements, as well as the average duration of the saccades and fixations influenced significantly the prediction of the postural score in RIL patients. While two patients with very low MATTIS-Attention sub score showed the lowest postural scores, no statistically significant relationship was found between the two outcomes.

Conclusion: These results highlight the significant relationship between the severity of balance deficits and the visual characteristics in RIL patients. It seems that increased balance impairment is coupled with a reduced focusing capacity in ecological tasks. Balance and eye movement recordings during a natural task could be a useful aspect of multidimensional scoring of the dysexecutive syndrome.

• attention
• balance control
• dysexecutive syndrome
• ecological tasks
• eye movements
• machine learning
• radiation-induced leukoencephalopathy

Among a sample of patient-informal caregiver dyads in the specific context of new diagnoses of high-grade glioma in the time-frame between diagnosis and the third month following diagnosis, we examine whether the coping strategies implemented by the patients and their caregivers influenced their own quality of life (QoL) and the QoL of their relatives.

Thirty-eight dyads with patients having recent diagnoses of high-grade glioma were involved in this longitudinal study. The self-reported data include QoL (Patient-Generated Index, EORTC QLQ-C30, and CareGiver Oncology Quality of Life), and coping strategies (BriefCope). Data were collected at T1 corresponding to the time-frame between diagnosis and postsurgical treatment initiation and T2 corresponding to the 3-month post-inclusion follow-up.

Coping strategies based on social support and avoidance were the least used at baseline and the 3-month follow-up, both for patients and caregivers. At the 3-month follow-up, the use of social support at baseline was significantly related to lower scores of QoL for the patients and with higher QoL for the caregivers. For the patient, the use of problem-solving or positive thinking at baseline was not related to his/her QoL, while it was related to more satisfactory QoL scores for the caregiver. The use of avoidance at baseline was linked to a higher 3-month QoL for the patients and a lower 3-month QoL for the caregivers. Using the specific dyadic analyses (actor–partner interdependence model), the 3-month patient’s QoL was lower (β = − 0.322; p = 0.03) when the patient mobilized the social support strategy at baseline, but was higher(β = 0.631; p < 10^− 3) when his/her informal caregiver used this strategy. After adjustment for sex, age, and baseline PGI score, the link between high use of the social support strategy at baseline by the caregiver and the patient’s 3-month QoL, remained present (positive partner effect; β =0.675; p < 10^− 3).

The QoL for patients and their informal caregivers since the time of diagnosis is directly related to the use of coping strategies based on social support at time of diagnosis.

• Caregivers
• Coping
• Dyads
• High-grade gliomas
• Quality of life
• Social support

• Cognition
• Glioma
• Individual differences
• Neuropsychological tests
• Neurosurgery
• Reliable change index